Enterococcus: Difference between revisions

From IDWiki
Enterococcus
mNo edit summary
No edit summary
 
(2 intermediate revisions by the same user not shown)
Line 22: Line 22:
**Less susceptible to antibiotics
**Less susceptible to antibiotics
**Most common VRE
**Most common VRE
*[[Enterococcus avium]]
*[[Enterococcus gallinarum]]
*[[Enterococcus gallinarum]]
*[[Enterococcus casseliflavus]]
*[[Enterococcus casseliflavus]]
Line 43: Line 44:


*[[Is treated by::Daptomycin]], [[Is treated by::doxycycline]], [[Is treated by::linezolid]], [[Is treated by::tedizolid]], [[Is treated by::oritavancin]], [[Is treated by::quinupristin-dalfopristin]] (for ''E. faecium'')
*[[Is treated by::Daptomycin]], [[Is treated by::doxycycline]], [[Is treated by::linezolid]], [[Is treated by::tedizolid]], [[Is treated by::oritavancin]], [[Is treated by::quinupristin-dalfopristin]] (for ''E. faecium'')
*For VanC isolates, [[ampicillin]] or [[penicillin]] is preferred, and [[daptomycin]] susceptibility is often retained[[CiteRef::jorgensen2003in]]


{{DISPLAYTITLE:''Enterococcus''}}
{{DISPLAYTITLE:''Enterococcus''}}

Latest revision as of 20:36, 23 September 2024

Background

Microbiology

  • Genus of facultative anaerobic, non-spore-forming, alpha- or gamma-hemolytic, catalase negative, Gram-positive cocci
  • Grows on bile esculin agar
  • PYR positive
  • Most are Lancefield group D
  • Commensal gut flora
  • Increasing antibiotic resistance

Species

Vancomycin Resistance

  • Vancomycin binds to d-Ala-d-Ala pentapeptids, interfering with cell wall synthesis
  • VanA: most common. Mutation to d-Ala-d-Lac, leading to high resistance to glycopeptides.
  • VanB: more common in E. faecium in Australia
  • VanC: chromosomal resistance on E. gallinarum and E. casseliflavus

Management

VRE

References

  1. ^  James H. Jorgensen, Sharon A. Crawford, Cynthia C. Kelly, Jan E. Patterson. In VitroActivity of Daptomycin against Vancomycin-Resistant Enterococci ofVarious Van Types and Comparison of Susceptibility TestingMethods. Antimicrobial Agents and Chemotherapy. 2003;47(12):3760-3763. doi:10.1128/aac.47.12.3760-3763.2003.